Menu Search
Equities

Hua Medicine

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2552:HKG.HS

Hua Medicine

Actions
  • Price (HKD)3.04
  • Today's Change-0.08 / -2.56%
  • Shares traded2.12m
  • 1 Year change+106.80%
  • Beta1.7084
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Hua Medicine is an investment holding company primarily engaged in the development and commercialization of oral drug for the treatment of Type 2 diabetes. The Company is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)419.81m
  • Net income in HKD1.22bn
  • Incorporated2009
  • Employees285.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.